Medical News

RSS

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe’s proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.

10 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

Capsule launches new Enterprise Medical Device Connectivity Solution

Capsule (www.capsuletech.com), the leading provider of medical device connectivity, today announces the release of their new Enterprise Medical Device Connectivity Solution enabled by the Capsule Neuron™.

10 Sep 2009

Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.

10 Sep 2009

Addressing employee mental health problems increases productivity: Researches

Effective treatment for employee mental health problems leads to significant improvements in productivity, according to a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

10 Sep 2009

Research on the impact of anti-smoking law in public places reveals that 5% of waiters have stopped smoking

Researchers from the Catalan Institute of Oncology have studied the impact of the law banning smoking in public places such as bars and restaurants on those working in these places. The results are positive - 5% of waiters have stopped smoking, and the number of cigarettes smoked by those who still smoke has fallen by almost 9%.

10 Sep 2009

First edition: September 10, 2009

In response to President Obama's joint address to Congress last night, the headlines are chock full of news, analysis, fact-checkers and inventories of cheers and jeers.

10 Sep 2009

Continucare Corporation announces fourth quarter and full-year results

Continucare Corporation (NYSE Amex:CNU) today reported financial results for its fourth quarter and fiscal year ended June 30, 2009.

10 Sep 2009

CTD Holdings reports second-quarter fiscal 2009 results

CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced today its second quarter results of operations.

10 Sep 2009

Amedisys in negotiations with Hackensack University Medical Center to acquire its home health operations

Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health and hospice nursing companies, today announced that it is in discussions to acquire the home health operations of Hackensack University Medical Center.

10 Sep 2009

GENova Biotherapeutics files patent to combat breast cancer

(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has filed a patent for a potential blockbuster drug target that combats breast cancer.

10 Sep 2009

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

St. Vincent develops the first-ever HIV educational widget

Saint Vincent Catholic Medical Centers and the New York State Department of Health (DOH) today unveiled a novel Web-based technology to rapidly instruct health care providers throughout New York State about HIV diagnosis and prevention.

10 Sep 2009

Health care reform should tackle food safety

Linda Rivera’s excruciating case of food poisoning (Severe Case Gives Context to Issue of Food Safety Washington Post 9/1/09) should shine some light on a crucial reality that is missing from most health care reform plans: you can’t fix America’s health care unless you provide Americans with a safe food supply.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

CBO reports cash shortfall for Social Security; seniors could face benefit cuts

Social Security will face a cash shortfall for the first time in decades next year, according to a little noticed report released late last month by the Congressional Budget Office (CBO).

10 Sep 2009

Third-quarter fiscal 2009 results announced by MDS

MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today reported financial results for the three-month period ended July 31, 2009. MDS reported total revenue of $199 million, a net loss of $62 million and a loss per share of $0.51 for the third quarter of 2009, compared with $252 million in total revenue, a net loss of $10 million and a loss per share of $0.08 for the same period last year.

10 Sep 2009

The Center for Justice & Democracy opposes President Obama's medical malpractice proposal

The Center for Justice & Democracy strongly opposes President Obama's plan to implement Bush Administration measures to limit the legal rights of severely injured patients, which has become part of the health care discussion apparently as a bargaining chip to reduce Republican opposition to much needed health care reform.

10 Sep 2009

FDA removes clinical hold on HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.

10 Sep 2009

NHSA and Together Rx Access collaborate to improve prescription access

The National Head Start Association (NHSA) and Together Rx Access announced today a collaboration to launch the Together Rx Access(R) FOR HEAD START Card to help eligible uninsured individuals and families associated with Head Start access immediate and meaningful savings on prescription medicines and products right at their neighborhood pharmacies.

10 Sep 2009